Evidence map›Paper›PMID 34989778›Full record

Trial reportJAMA oncology2022

Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators, Michelle Ghert, Patricia Schneider, Gordon Guyatt, Lehana Thabane, Roberto Vélez, Timothy O'Shea, R Lor Randall, Robert Turcotte, David Wilson and 15 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in JAMA oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479283 (Prophylactic Antibiotic Regimens in Tumor Surgery), which is not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01479283 phase3completednot on this map

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements

TypeinterventionalSponsorMcMaster UniversityRan2013 to 2021Enrolled602ConditionsInfection, Bone NeoplasmsArms24-Hour Prophylactic Cefazolin* Antibiotic Regimen, 5-Days Prophylactic Cefazolin* Antibiotic Regimen
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 90 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Endoprosthetic Reconstruction for Proximal Humerus Tumors.Current reviews in musculoskeletal medicine · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 6 countries.

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators
Michelle GhertDivision of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Patricia SchneiderDivision of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Gordon GuyattDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Lehana ThabaneDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
Roberto VélezHospital Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
Timothy O'SheaDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
R Lor RandallDepartment of Orthopaedic Surgery, University of California Davis Health, Sacramento.
Robert TurcotteDivision of Orthopaedic Surgery, Department of Surgery, McGill University, Montreal, Quebec, Canada.
David WilsonDivision of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Jay S WunderUniversity of Toronto Musculoskeletal Oncology Unit, Mount Sinai Hospital, Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
André Mathias BaptistaInstituto de Ortopedia e Traumatologia do Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
Edward Y ChengDepartment of Orthopaedic Surgery, University of Minnesota, Minneapolis.
Yee-Cheen DoungDepartment of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland.
Peter C FergusonUniversity of Toronto Musculoskeletal Oncology Unit, Mount Sinai Hospital, Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Victoria GiglioDivision of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
James HaydenDepartment of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland.
Diane Heels-AnsdellDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
Shah Alam KhanDepartment of Orthopaedics, All India Institute of Medical Sciences, Delhi, India.
Venkatesan Sampath KumarDepartment of Orthopaedics, All India Institute of Medical Sciences, Delhi, India.
Paula McKayDivision of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Benjamin MillerDepartment of Orthopaedics and Rehabilitation, University of Iowa, Iowa City.
Michiel van de SandeDepartment of Orthopaedic Surgery, Leids Universitair Medisch Centrum, Leiden, the Netherlands.
Juan P ZumárragaInstituto de Ortopedia e Traumatologia do Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
Mohit BhandariDivision of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Impact · CAMcMaster University · CAMount Sinai Hospital · CAAll India Institute of Medical Sciences · INOregon Health & Science University · USUniversidade de São Paulo · BRMcGill University · CAUniversity of Iowa · USUniversity of Minnesota · USVall d'Hebron Institut de Recerca · ESUniversity of California, Davis · USLeiden University Medical Center · NL

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
6 · The paper itself

Abstract

importanceThe use of perioperative, prophylactic, intravenous antibiotics is standard practice to reduce the risk of surgical site infection after oncologic resection and complex endoprosthetic reconstruction for lower extremity bone tumors. However, evidence guiding the duration of prophylactic treatment remains limited.

objectiveTo assess the effect of a 5-day regimen of postoperative, prophylactic, intravenous antibiotics compared with a 1-day regimen on the rate of surgical site infections within 1 year after surgery. DESIGN, SETTING, AND

participantsThis randomized clinical superiority trial was performed at 48 clinical sites in 12 countries from January 1, 2013, to October 29, 2019. The trial included patients with a primary bone tumor or a soft tissue sarcoma that had invaded the femur or tibia or oligometastatic bone disease of the femur or tibia with expected survival of at least 1 year who required surgical management by excision and endoprosthetic reconstruction. A total of 611 patients were enrolled, and 7 were excluded for ineligibility.

interventionsA 1- or 5-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime) that began within 8 hours after skin closure and was administered every 8 hours thereafter. Those randomized to the 1-day regimen received identical saline doses every 8 hours for the remaining 4 days; patients, care providers, and outcomes assessors were blinded to treatment regimen. MAIN OUTCOMES AND MEASURES: The primary outcome in this superiority trial was a surgical site infection (superficial incisional, deep incisional, or organ space) classified according to the criteria established by the Centers for Disease Control and Prevention within 1 year after surgery. Secondary outcomes included antibiotic-related complications, unplanned additional operations, oncologic and functional outcomes, and mortality.

resultsOf the 604 patients included in the final analysis (mean [SD] age, 41.2 [21.9] years; 361 [59.8%] male; 114 [18.9%] Asian, 43 [7.1%] Black, 34 [5.6%] Hispanic, 15 [2.5%] Indigenous, 384 [63.8%] White, and 12 [2.0%] other), 293 were randomized to a 5-day regimen and 311 to a 1-day regimen. A surgical site infection occurred in 44 patients (15.0%) allocated to the 5-day regimen and in 52 patients (16.7%) allocated to the 1-day regimen (hazard ratio, 0.93; 95% CI, 0.62-1.40; P = .73). Antibiotic-related complications occurred in 15 patients (5.1%) in the 5-day regimen and in 5 patients (1.6%) allocated to the 1-day regimen (hazard ratio, 3.24; 95% CI, 1.17-8.98; P = .02). Other secondary outcomes did not differ significantly between treatment groups. CONCLUSIONS AND RELEVANCE: This randomized clinical trial did not confirm the superiority of a 5-day regimen of postoperative intravenous antibiotics over a 1-day regimen in preventing surgical site infections after surgery for lower extremity bone tumors that required an endoprosthesis. The 5-day regimen group had significantly more antibiotic-related complications.

trial registrationClinicalTrials.gov Identifier: NCT01479283.

Indexed as

Antibiotic ProphylaxisBone NeoplasmsAdultAnti-Bacterial AgentsHumansLower ExtremityMaleSurgical Wound InfectionUnited StatesAnti-Bacterial Agents

Identifiers

PMID34989778
PMCPMC8739829
OpenAlexW4205698721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.